3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
44
Prostatic Neoplasms, Castration-Resistant
6
Neoplasm Metastasis
4
Metastatic Castration-resistant Prostate Cancer
4
Prostate Carcinoma Metastatic to the Bone
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Hormone Refractory Prostate Cancer
2
Carcinoma, Renal Cell
2
Bone Metastatic Castration-resistant Prostate Cancer
2
Prostate Cancer Metastatic to Bone
1
Prostate Adenocarcinoma
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Lymphatic Metastasis
1
Fractures, Bone
1
Castration-resistant Prostate Cancer
1
Castrate-Resistant Prostate Cancer
1
Bony Metastases From Castrate Refractory Prostate Cancer
1
Bone Neoplasms
1
Bone Metastases
1
Advanced Prostate Cancer
1
Interventions
radium Ra 223 dichloride
2
pembrolizumab
2
enzalutamide
2
abiraterone
2
Injections
2
Abiraterone Acetate
2
niraparib
1
efineptakin alfa
1
darolutamide
1
capivasertib
1
cabazitaxel
1
apalutamide
1
Solutions
1
Radium-223
1
Prednisone
1
Pluvicto
1
PSMA-11
1
Lutetium-177
1
Lutetium
1
Docetaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer (mCRPC)
×
radium Ra 223 dichloride
×
Genitourinary
×
Clear all
NCT03903835
2025-04-09
ProBio
Karolinska Institutet
Phase 3
Recruiting
750 enrolled
NCT03896984
2021-12-29
PHENIX
Bayer
Completed
346 enrolled